Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (174)	1/11/2006 5:21:28 PM
From: tuck	Respond to of 332

>>Form 8-K for ATHEROGENICS INC 11-Jan-2006 Sale of Equity Item 3.02. Unregistered Sales of Equity Securities. On January 10, 2006, AtheroGenics, Inc. (the Registrant) entered into a letter agreement with QVT Fund LP (the QVT Holder) pursuant to which the parties agreed to exchange $11.075 million in aggregate principal amount of the Registrants 4.50% convertible notes due 2008 held by the QVT Holder for 858,313 shares of the Registrants common stock, no par value per share (the QVT Exchange). The QVT Exchange will be made pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the Act), afforded by Section 3(a)(9) of the Act, as no commission or other remuneration will be paid or given directly or indirectly by the Registrant for such QVT Exchange. On January 10, 2006, the Registrant entered into a letter agreement with Deutsche Bank AG, London (the DB Holder) pursuant to which the parties agreed to exchange $2.925 million in aggregate principal amount of the Registrants 4.50% convertible notes due 2008 held by the DB Holder for 226,687 shares of the Registrants common stock, no par value per share (the DB Exchange). The DB Exchange will be made pursuant to the exemption from the registration requirements of the Act, afforded by Section 3(a)(9) of the Act, as no commission or other remuneration will be paid or given directly or indirectly by the Registrant for such DB Exchange. << Apparently the conversion price is $12.9. More shares, less debt . . . Cheers, Tuck